Cajeta, Arian .
HRN: 22-34-64 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/01/2023
MUPIROCIN 2%, 15G (TUBE)
01/01/2023
01/07/2023
TOPICAL
2%
BID
Infiltrated Post IV Site
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes